GMED Beat EPS by 22% and Raised Guidance. The Stock Moved 1.5%. Here's Why.

Globus Medical beat on EPS by 22% and raised full-year guidance. The stock moved 1.5%. That's the disconnect.

GMED traded at $82.35 on Friday, barely up from the $81.08 close the day before its Q2 report. Non-GAAP EPS hit a record $1.34 versus $1.10 consensus — a 22% beat. Revenue of $789.6 million topped estimates. Adjusted EBITDA margin — earnings before interest, taxes, depreciation, and amortization, a rough cash-proxy of operating performance — expanded 740 basis points year-over-year to 35.4%. Management raised full-year non-GAAP EPS guidance from $4.70–$4.80 to $4.95–$5.05. The market shrugged.

The shrug makes sense only if you're anchoring on the wrong variable.

The story isn't Nevro's 14.3% sales decline or Enabling Technologies' 26% revenue drop. The story is the base business — excluding the Nevro acquisition — growing 9% with margins expanding for the seventh consecutive quarter. That's the variable that drives earnings power. The market is pricing the drag instead of the engine.

1. Margin expansion is the real story, and it's ahead of plan.

Adjusted gross margin hit 69.4% in Q2, up 200 basis points from a year earlier. SG&A fell to 36.3% of sales from 40.7%. R&D declined to 4.6% from 5.4% as merger synergies came through. Adjusted EBITDA margin expanded from 28% to 35.4% in twelve months. CEO Keith Pfeil said the company has achieved mid-30s EBITDA margins ahead of its original three-year post-merger target.

The EPS guidance raise was attributed directly to this margin trajectory, not buybacks or one-off items. CFO Kyle Kline said the revision reflects "a favorable increase in expectations from the margin expansion and operating leverage seen in the first half of 2026". That matters because margin expansion of this magnitude in a medtech company usually signals structural operating leverage — fixed costs are spreading over a growing revenue base and the merger is delivering on its cost synergy promises. Free cash flow margins are tracking at 19.4% for the trailing twelve months, with FCF growth at 41% year-over-year.

2. The growth engine is intact — and international is the unsung driver.

U.S. spine grew 7% in Q2, the fifth consecutive quarter of above-market growth. That's solid, and management was honest about it slowing from the prior 10% rate with tougher year-over-year comparisons ahead in the second half. But international spine grew 14% as-reported (12% constant currency). Overall international revenue grew 18%.

EMEA posted mid-teens growth driven by Italy, Spain, and Poland. APAC showed broad-based gains. LATAM growth was led by Brazil and Colombia. Management emphasized "going deeper" in existing territories with improved inventory availability and set deliveries as catalysts. They're targeting sustained double-digit growth in international spine for the back half of the year.

International is now a meaningful growth vector, not a rounding error. When the U.S. comp gets harder, international momentum carries the base case.

3. The Nevro drag is temporary, not structural.

Nevro sales fell 14.3% year-over-year and declined sequentially by $1.7 million. Trial volume recovery isn't expected until late Q4. That's a headwind, and management priced it into the decision to keep revenue guidance unchanged.

But Nevro's EBITDA margin improved from -1.4% to 22.4% due to structural cost controls enacted in 2025. The cost structure is fixed even if revenue hasn't recovered yet. Once trial volume normalizes, Nevro becomes accretive rather than dilutive. The question isn't whether Nevro's business model works — it's whether the trial distribution channel recovers, and management's late-Q4 timeline is specific enough to track.

4. Enabling Technologies is a transition, not a collapse.

Enabling Technologies revenue dropped 26% in Q2 to $26.1 million. The headline looks bad. The mechanism is intentional: Globus is shifting away from outright capital equipment sales toward leasing and renting models. Total unit deployments of its ExcelsiusGPS robotic navigation system grew 25% year-over-year and 11% sequentially despite the revenue decline. Over 137,000 procedures have been performed using Globus robotic navigation technologies.

The model swap hurts short-term revenue recognition but builds a recurring implant, disposable, and service pull-through stream once equipment is in-hospital and staff are trained. The stock penalizes transition years. The math rewards companies that survive them.

The bear case has weight.

U.S. spine growth slowed from 10% to 7%, and management warned of tougher comps in H2. R&D spending is ramping back up to 5–6% of sales in the second half, which will pressure margins after seven quarters of expansion. Enabling Technologies is a revenue hole until the leasing model proves it can replace outright sales. Nevro remains unresolved through Q4. Sell-side analysts project only 4.8% revenue growth for the next twelve months — a meaningful deceleration from the double-digit pace Globus ran for much of its post-merger period.

If U.S. spine stalls, Nevro doesn't recover, and Enabling Tech doesn't stabilize, the base case narrows fast.

The valuation math.

GMED trades at approximately 20x forward earnings, with a PEG ratio of 0.41 — forward PE divided by the expected earnings growth rate, where a reading well below 1.0 suggests the stock is cheap relative to its growth trajectory. EV/EBITDA sits at 11.2x. Compare that to Stryker at 34.9x PE and 20.9x EV/EBITDA, or Zimmer Biomet at 22.8x PE and 11.0x EV/EBITDA. The stock is trading below its own growth rate, which is the textbook definition of a valuation disconnect.

The company is also deploying 40% of its free cash flow to share buybacks year-to-date — $136 million on 1.6 million shares in Q2 alone — having repurchased over 50% of the dilution from the NuVasive merger since September 2023. That's valuation support built into the capital allocation.

The setup.

GMED isn't a turnaround story. It's a company that executed on its margin expansion plan ahead of schedule, beat on EPS by 22%, raised guidance, and got ignored because two smaller segments are struggling and consensus expects growth to decelerate next year. The base spine business is growing 9%, margins are expanding structurally, international is providing a new growth leg, and the stock trades at 20x forward earnings with a 0.41 PEG.

The stock could pull back further if the H2 U.S. comps disappoint or Nevro's trial recovery slides beyond Q4. But the forward math already assumes a deceleration that management's execution is fighting against. At roughly 20x EPS on $5.00 of expected 2026 earnings, the stock doesn't price in the margin trajectory or the international momentum that's already happening.

AInvest's aggregate signal labels GMED a Buy, with a high fundamental rating and strong liquidity score — consistent with the math even if the opaque scoring methodology doesn't prove anything on its own.

The break condition is simpler than the narrative: if U.S. spine holds above 5% in H2 and Nevro stabilizes by late Q4 as management projected, the gap between execution and valuation closes fast. If either one breaks, the thesis needs reassessment.